A novel biomarker in first-degree relatives of patients with Alzheimer's disease: Macular pigment optical density

IF 1.1 4区医学 Q3 OPHTHALMOLOGY

Journal Francais D Ophtalmologie Pub Date : 2025-08-04 DOI:10.1016/j.jfo.2025.104617

H. Altinkaynak, O. Sayin

{"title":"A novel biomarker in first-degree relatives of patients with Alzheimer's disease: Macular pigment optical density","authors":"H. Altinkaynak, O. Sayin","doi":"10.1016/j.jfo.2025.104617","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>The goal of this study was to evaluate the level of macular pigment optical density (MPOD) in asymptomatic cognitively healthy first-degree relatives of patients with sporadic Alzheimer's disease (AD).</div></div><div><h3>Methods</h3><div>One-hundred four subjects who were asymptomatic cognitively healthy first-degree relatives of patients with sporadic AD (study group) and 80 healthy individuals (control group) were enrolled in the study. MPOD measurements of both groups were obtained with the MPSII device (MPSII V, Elektron Eye Technology, Cambridge, UK).</div></div><div><h3>Results</h3><div>The mean MPOD was 0.46±0.10 in the study group and 0.64±0.14 in the control group. MPOD values were found to be statistically significant when compared between the two groups (<em>P</em>      =0,028).</div></div><div><h3>Conclusion</h3><div>La MPOD pourrait être un nouveau biomarqueur non invasif pour le diagnostic précoce, la surveillance et le dépistage de la maladie avant l’apparition des symptômes cliniques chez les individus présentant un risque génétique élevé de développer la MA.</div></div>","PeriodicalId":14777,"journal":{"name":"Journal Francais D Ophtalmologie","volume":"48 7","pages":"Article 104617"},"PeriodicalIF":1.1000,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal Francais D Ophtalmologie","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0181551225001998","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

The goal of this study was to evaluate the level of macular pigment optical density (MPOD) in asymptomatic cognitively healthy first-degree relatives of patients with sporadic Alzheimer's disease (AD).

Methods

One-hundred four subjects who were asymptomatic cognitively healthy first-degree relatives of patients with sporadic AD (study group) and 80 healthy individuals (control group) were enrolled in the study. MPOD measurements of both groups were obtained with the MPSII device (MPSII V, Elektron Eye Technology, Cambridge, UK).

Results

The mean MPOD was 0.46 ± 0.10 in the study group and 0.64 ± 0.14 in the control group. MPOD values were found to be statistically significant when compared between the two groups (P = 0.028).

Conclusion

MPOD may be a new noninvasive biomarker for early diagnosis, monitoring, and screening of the disease before the onset of clinical symptoms in individuals at high genetic risk of developing AD.

Objectif

L’objectif de cette étude était d’évaluer le niveau de densité optique du pigment maculaire (MPOD) chez des parents au premier degré asymptomatiques et en bonne santé cognitive des patients atteints de la maladie d’Alzheimer (MA) sporadique.

Méthodes

Cent quatre sujets ayant des parents au premier degré asymptomatiques et en bonne santé cognitive de patients atteints de MA sporadique (groupe d’étude) et quatre-vingts individus en bonne santé (groupe témoin) ont été inclus dans l’étude. Les mesures de MPOD des deux groupes ont été obtenues avec l’appareil MPSII (MPSII V, Elektron Eye Technology, Cambridge, Royaume-Uni).

Résultats

La MPOD moyenne était de 0,46 ± 0,10 dans le groupe d’étude et de 0,64 ± 0,14 dans le groupe témoin. Les valeurs de MPOD se sont avérées statistiquement significatives lorsqu’elles ont été comparées entre les deux groupes (p = 0,028).

Conclusion

La MPOD pourrait être un nouveau biomarqueur non invasif pour le diagnostic précoce, la surveillance et le dépistage de la maladie avant l’apparition des symptômes cliniques chez les individus présentant un risque génétique élevé de développer la MA.

查看原文本刊更多论文

阿尔茨海默病患者一级亲属的一种新的生物标志物：黄斑色素光密度

目的评价散发性阿尔茨海默病（AD）患者无症状认知健康一级亲属黄斑色素光密度（MPOD）水平。方法选取散发性AD患者无症状认知健康的一级亲属104人（研究组）和健康人群80人（对照组）作为研究对象。两组的MPOD测量均使用MPSII设备（MPSII V, Elektron Eye Technology, Cambridge， UK）。结果研究组平均MPOD为0.46±0.10，对照组为0.64±0.14。两组患者MPOD值比较，差异有统计学意义（P = 0.028）。结论mpod可能是一种新的无创生物标志物，可用于阿尔茨海默病高遗传风险人群在临床症状出现前的早期诊断、监测和筛查。目的探讨老年痴呆症（MA）散发性痴呆患者的抑郁症状、无症状症状及认知障碍患者的抑郁症状、抑郁抑郁症状、抑郁抑郁症状、抑郁抑郁症状、抑郁抑郁症状、抑郁抑郁症状、抑郁抑郁症状、抑郁抑郁症状、抑郁抑郁症状、抑郁抑郁症状、抑郁抑郁症状、抑郁抑郁症状、抑郁抑郁症状、抑郁抑郁症状、抑郁抑郁症状。四分之一的研究对象包括：无症状的父母、无症状的父母、有认知障碍的患者、散发性的无症状的父母和有认知障碍的患者（四分之一的研究对象）、有个体的无症状的父母（四分之一的研究对象）、有抑郁的父母（四分之一的研究对象）、有抑郁的父母（四分之一的研究对象）、有抑郁的父母（四分之一的研究对象）。Les measures de MPOD des deux groups ont。MPOD - moyenne - sade为0.46±0.10 d组- sade - sade为0.64±0.14 d组- sade - sade。在两个组中，MPOD的value值在统计上具有显著性（p = 0,028）。ConclusionLa MPOD新的biomarqueur非invasif倒可能诊断precoce, le depistage de la la监测等病的l 'apparition des症状倩碧在每个presentant联合国有伤genetique与德开发马。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal Francais D Ophtalmologie 医学-眼科学

CiteScore

1.10

自引率

8.30%

发文量

317

审稿时长

49 days

期刊介绍： The Journal français d''ophtalmologie, official publication of the French Society of Ophthalmology, serves the French Speaking Community by publishing excellent research articles, communications of the French Society of Ophthalmology, in-depth reviews, position papers, letters received by the editor and a rich image bank in each issue. The scientific quality is guaranteed through unbiased peer-review, and the journal is member of the Committee of Publication Ethics (COPE). The editors strongly discourage editorial misconduct and in particular if duplicative text from published sources is identified without proper citation, the submission will not be considered for peer review and returned to the authors or immediately rejected.